The Annals Take our Readership Survey!
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

The Annals of Pharmacotherapy: Vol. 33, No. 6, pp. 697-700. DOI 10.1345/aph.18282
© 1999 Harvey Whitney Books Company.
This Article
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Marcus, E.
Right arrow Articles by Zislin, J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marcus, E.
Right arrow Articles by Zislin, J

Research Articles

Marked elevation of serum creatine kinase associated with olanzapine therapy

EL Marcus, A Vass, and J Zislin

OBJECTIVE: To report a case of marked elevation of serum creatine kinase (CK) associated with olanzapine therapy. CASE SUMMARY: A 39-year-old white Jewish schizophrenic man treated with olanzapine developed an elevated serum CK concentration with a peak concentration of 4000 IU/L (normal < 230). No other diagnostic criteria for neuroleptic malignant syndrome (NMS) were present. On discontinuation of the drug, serum CK concentrations returned to normal within eight days. DISCUSSION: Olanzapine, like other atypical antipsychotic drugs, may cause muscle injury with concomitant elevations of serum CK of muscle origin. We suggest that in patients treated with olanzapine, CK concentrations should be checked on initiation of therapy, within the first 48 hours, and weekly thereafter for at least one month. In addition, patients with clinical signs suggestive of NMS should be monitored more carefully. For those patients with a history of NMS, or even of isolated serum CK elevation during antipsychotic therapy, follow-up should be stricter. CONCLUSIONS: Marked elevation of serum CK may be a possible complication of olanzapine therapy.


This article has been cited by other articles:


Home page
 J Intensive Care MedHome page
M. K. Varma, K. Connolly, and B. Fulton
Life-Threatening Hyperglycemia and Acidosis Related to Olanzapine: A Case Report and Review of the Literature
J Intensive Care Med, January 1, 2007; 22(1): 52 - 55.
[Abstract] [PDF]

Home page
 Hum Exp ToxicolHome page
W S Waring, J Wrate, and D N Bateman
Olanzapine overdose is associated with acute muscle toxicity
Human and Experimental Toxicology, December 1, 2006; 25(12): 735 - 740.
[Abstract] [PDF]

Home page
 The Annals of PharmacotherapyHome page
C. J Lim, C. Trevino, and R. R Tampi
Can Olanzapine Cause Delirium in the Elderly?
Ann. Pharmacother., January 1, 2006; 40(1): 135 - 138.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
A. N Zaidi
Rhabdomyolysis After Correction of Hyponatremia in Psychogenic Polydipsia Possibly Complicated by Ziprasidone
Ann. Pharmacother., October 1, 2005; 39(10): 1726 - 1730.
[Abstract] [Full Text] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 1999 by Harvey Whitney Books Company.